Eman Alabsawy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Eman Alabsawy has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Rajiv Jalan
Institute for Liver and Digestive Health, University College Hospital, Royal Free Campus, London, UK
5 shared publications Shalimar
All India Inst Med Sci, Dept Gastroenterol, New Delhi, India
4 shared publications- Andrew Hall
Sheila Sherlock Liver Centre, Royal Free London NHS Foundation Trust, London, UK
1 shared publication - Annarein Johanna Catharina Kerbert
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
1 shared publication - Antonella Putignano
Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium; Department of Hepatogastroenterology, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium
1 shared publication Banwari Agarwal
Liver Failure Group, Institute for Liver and Digestive Health University College London London UK
1 shared publication
Latest Publications
- 16 April 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (9) , 1231-1232
Letter: de novo infection in hepatic encephalopathy—The culprit or the victim? Authors' reply
- 16 April 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (9) , 1231-1232
Letter: de novo infection in hepatic encephalopathy—The culprit or the victim? Authors' reply
- 4 March 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (6) , 746-747
Editorial: infections and hepatic encephalopathy—does the chicken or the egg come first? A novel perspective at the horizon. Authors’ reply
LINKED CONTENT: This article is linked to Alabsawy et al papers. To view these articles, visit https://doi.org/10.1111/apt.16790 and https://doi.org/10.1111/apt.16809
- 4 March 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (6) , 746-747
Editorial: infections and hepatic encephalopathy—does the chicken or the egg come first? A novel perspective at the horizon. Authors’ reply
LINKED CONTENT: This article is linked to Alabsawy et al papers. To view these articles, visit https://doi.org/10.1111/apt.16790 and https://doi.org/10.1111/apt.16809
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 751-752
Potential novel approaches to prevent the risk of infection in patients with variceal bleeding
- 1 March 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 76 (3) , 751-752
Potential novel approaches to prevent the risk of infection in patients with variceal bleeding
- Open Access
- 1 February 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (6) , 722-732
Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation
Background The occurrence of overt hepatic encephalopathy (OHE) is associated with increased mortality. HE is commonly precipitated by infection, but whether HE predisposes to new infection is unclear. This study aimed to test if OHE predisposes to de novo infection during hospitalisation and its association with short-term mortality. Aims and Methods Seven hundred and fifty-nine consecutive patients were identified at two institutions from prospectively maintained clinical databases of cirrhotic patients admitted with acute decompensation (AD). Infection and HE data were collected on the day of admission, and the occurrence of de novo infections was assessed for 28 days after admission. EASL-CLIF organ failure criteria were used to determine the presence of organ failures. Multivariable analysis using the logistic regression model was used to assess predictors of 28-day mortality and de novo infection. Results Patients were divided into four groups; no baseline OHE or infection (n = 352); OHE with no baseline Infection (n = 221); no OHE but baseline infection (n = 100) and OHE with baseline infection (n = 86). On multivariate analyses, OHE (OR, 1.532 [95% CI, 1.061–2.300, P = 0.024]), and admission to ITU (OR, 2.303 [95% CI, 1.508–3.517, P < 0.001]) were independent risk factors for de novo infection. 28-day mortality was 25.3%, 60.2%, 55.0% and 72.1% in the 4-groups respectively. Age, INR and creatinine were independently predictive of mortality. The presence of overt HE, infection, coagulation, kidney, circulatory, respiratory and liver failures were significantly associated with higher mortality. Conclusion OHE is an independent risk factor for de novo infection in cirrhotic patients with AD.
- 1 February 2022
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 55 (6) , 722-732
Open AccessOvert hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation
Background The occurrence of overt hepatic encephalopathy (OHE) is associated with increased mortality. HE is commonly precipitated by infection, but whether HE predisposes to new infection is unclear. This study aimed to test if OHE predisposes to de novo infection during hospitalisation and its association with short-term mortality. Aims and Methods Seven hundred and fifty-nine consecutive patients were identified at two institutions from prospectively maintained clinical databases of cirrhotic patients admitted with acute decompensation (AD). Infection and HE data were collected on the day of admission, and the occurrence of de novo infections was assessed for 28 days after admission. EASL-CLIF organ failure criteria were used to determine the presence of organ failures. Multivariable analysis using the logistic regression model was used to assess predictors of 28-day mortality and de novo infection. Results Patients were divided into four groups; no baseline OHE or infection (n = 352); OHE with no baseline Infection (n = 221); no OHE but baseline infection (n = 100) and OHE with baseline infection (n = 86). On multivariate analyses, OHE (OR, 1.532 [95% CI, 1.061–2.300, P = 0.024]), and admission to ITU (OR, 2.303 [95% CI, 1.508–3.517, P < 0.001]) were independent risk factors for de novo infection. 28-day mortality was 25.3%, 60.2%, 55.0% and 72.1% in the 4-groups respectively. Age, INR and creatinine were independently predictive of mortality. The presence of overt HE, infection, coagulation, kidney, circulatory, respiratory and liver failures were significantly associated with higher mortality. Conclusion OHE is an independent risk factor for de novo infection in cirrhotic patients with AD.
- 20 September 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (9) , e244805
Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism
Hepatopulmonary syndrome (HPS) is characterised by the development of intrapulmonary arteriovenous blood shunts and vascular dilatation with consequent hypoxaemia, usually in the context of end-stage liver disease (ESLD). The estimated incidence of HPS in ESLD has been reported to be 13%–47%. Chronic liver disease has been described in patients with hypothalamic–pituitary dysfunction, mainly in the form of non-alcoholic fatty liver disease due to metabolic syndrome, with occasional progression to cirrhosis. We report a challenging case of a 27-year-old man with a background of hypopituitarism with no known liver disease who presented with progressive dyspnoea and hypoxaemia and was eventually diagnosed with severe HPS.
- 20 September 2021
- Published by BMJ in BMJ Case Reports
- Vol. 14 (9) , e244805
Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism
Hepatopulmonary syndrome (HPS) is characterised by the development of intrapulmonary arteriovenous blood shunts and vascular dilatation with consequent hypoxaemia, usually in the context of end-stage liver disease (ESLD). The estimated incidence of HPS in ESLD has been reported to be 13%–47%. Chronic liver disease has been described in patients with hypothalamic–pituitary dysfunction, mainly in the form of non-alcoholic fatty liver disease due to metabolic syndrome, with occasional progression to cirrhosis. We report a challenging case of a 27-year-old man with a background of hypopituitarism with no known liver disease who presented with progressive dyspnoea and hypoxaemia and was eventually diagnosed with severe HPS.
- Open Access
- 27 August 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (6) , 100355
Biomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
- 27 August 2021
- Published by Elsevier in JHEP Reports
- Vol. 3 (6) , 100355
Open AccessBiomarkers of extracellular matrix formation are associated with acute-on-chronic liver failure
- 21 June 2018
- Published by Wiley in Liver International
- Vol. 38 (12) , 2228-2238
Long‐term outcome in patients with acute liver failure
Background & Aims: Acute liver failure patients who meet poor prognostic criteria have high early mortality without emergency liver transplantation. A recent study however, reported that patients that survive spontaneously have a poorer outcome compared with patients undergoing transplantation. In this single centre study, we aimed to confirm or refute this observation.Methods: Early survivors (acute liver failure patients who survived 90 days after the ICU admission) were assessed for long‐term outcomes in four distinctive cohorts, incorporating aetiology (Acetaminophen overdose or non‐Acetaminophen overdose), and management strategy (conservative or liver transplantation). Chi Squared or Fisher test were used to compare outcomes among the four cohorts (P < 0.05) and Kaplan–Meier curve (Log Rank test) to represent cumulative survival.Results: Two hundred consecutive acute liver failure patients between 1990 and 2014 were included; mean age 38.3, ±12.8, male 70, 35%. 124/200 (62%) early survivors were identified; 13/124 (10.5%) acetaminophen patients underwent transplantation and 48/124 (38.7%) survived spontaneously; 36/124 (29.0%) non‐acetaminophen underwent transplantation and 27/124 (21.8%) survived spontaneously. A total of 11/124 (8.9%) died subsequently (median survival 5.3± IQR 9.1), three spontaneous survivors and eight transplanted patients (P = 0.025); of the eight transplanted patients, six died of transplant related complications and two of suicide.Conclusion: The results of this study suggest that although liver transplantation is a life‐saving procedure for acute liver failure patients, they have a worse long‐term outcome compared with spontaneous survivors. Novel therapies to increase the percentage of spontaneous survivors are urgently needed.
- 21 June 2018
- Published by Wiley in Liver International
- Vol. 38 (12) , 2228-2238
Long‐term outcome in patients with acute liver failure
Background & Aims: Acute liver failure patients who meet poor prognostic criteria have high early mortality without emergency liver transplantation. A recent study however, reported that patients that survive spontaneously have a poorer outcome compared with patients undergoing transplantation. In this single centre study, we aimed to confirm or refute this observation.Methods: Early survivors (acute liver failure patients who survived 90 days after the ICU admission) were assessed for long‐term outcomes in four distinctive cohorts, incorporating aetiology (Acetaminophen overdose or non‐Acetaminophen overdose), and management strategy (conservative or liver transplantation). Chi Squared or Fisher test were used to compare outcomes among the four cohorts (P < 0.05) and Kaplan–Meier curve (Log Rank test) to represent cumulative survival.Results: Two hundred consecutive acute liver failure patients between 1990 and 2014 were included; mean age 38.3, ±12.8, male 70, 35%. 124/200 (62%) early survivors were identified; 13/124 (10.5%) acetaminophen patients underwent transplantation and 48/124 (38.7%) survived spontaneously; 36/124 (29.0%) non‐acetaminophen underwent transplantation and 27/124 (21.8%) survived spontaneously. A total of 11/124 (8.9%) died subsequently (median survival 5.3± IQR 9.1), three spontaneous survivors and eight transplanted patients (P = 0.025); of the eight transplanted patients, six died of transplant related complications and two of suicide.Conclusion: The results of this study suggest that although liver transplantation is a life‐saving procedure for acute liver failure patients, they have a worse long‐term outcome compared with spontaneous survivors. Novel therapies to increase the percentage of spontaneous survivors are urgently needed.